US Bipolar Disorders Treatment Market

ID: MRFR/Pharma/15118-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
US Bipolar Disorders Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Medication, Psychotherapy, Hospitalization, Electroconvulsive Therapy, Transcranial Magnetic Stimulation), By Medication Class (Mood Stabilizers, Antipsychotics, Antidepressants, Anticonvulsants), By Patient Age Group (Children, Adolescents, Adults, Elderly) and By Healthcare Setting (Outpatient, Inpatient, Residential Treatment Centers) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Treatment Type (USD Million)
      1. 4.1.1 Medication
      2. 4.1.2 Psychotherapy
      3. 4.1.3 Hospitalization
      4. 4.1.4 Electroconvulsive Therapy
      5. 4.1.5 Transcranial Magnetic Stimulation
    2. 4.2 Pharmaceutical, BY Medication Class (USD Million)
      1. 4.2.1 Mood Stabilizers
      2. 4.2.2 Antipsychotics
      3. 4.2.3 Antidepressants
      4. 4.2.4 Anticonvulsants
    3. 4.3 Pharmaceutical, BY Patient Age Group (USD Million)
      1. 4.3.1 Children
      2. 4.3.2 Adolescents
      3. 4.3.3 Adults
      4. 4.3.4 Elderly
    4. 4.4 Pharmaceutical, BY Healthcare Setting (USD Million)
      1. 4.4.1 Outpatient
      2. 4.4.2 Inpatient
      3. 4.4.3 Residential Treatment Centers
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Eli Lilly and Company (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Pfizer Inc. (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AstraZeneca PLC (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Johnson & Johnson (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bristol-Myers Squibb Company (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Novartis AG (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi S.A. (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Otsuka Pharmaceutical Co., Ltd. (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Teva Pharmaceutical Industries Ltd. (IL)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY MEDICATION CLASS
    4. 6.4 US MARKET ANALYSIS BY PATIENT AGE GROUP
    5. 6.5 US MARKET ANALYSIS BY HEALTHCARE SETTING
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 PHARMACEUTICAL, BY MEDICATION CLASS, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY MEDICATION CLASS, 2024 TO 2035 (USD Million)
    16. 6.16 PHARMACEUTICAL, BY PATIENT AGE GROUP, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
    18. 6.18 PHARMACEUTICAL, BY HEALTHCARE SETTING, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY MEDICATION CLASS, 2025-2035 (USD Million)
      3. 7.2.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
      4. 7.2.4 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US US Bipolar Disorders Treatment Market Segmentation

US Bipolar Disorders Treatment Market By Treatment Type (USD Million, 2025-2035)

  • Medication
  • Psychotherapy
  • Hospitalization
  • Electroconvulsive Therapy
  • Transcranial Magnetic Stimulation

US Bipolar Disorders Treatment Market By Medication Class (USD Million, 2025-2035)

  • Mood Stabilizers
  • Antipsychotics
  • Antidepressants
  • Anticonvulsants

US Bipolar Disorders Treatment Market By Patient Age Group (USD Million, 2025-2035)

  • Children
  • Adolescents
  • Adults
  • Elderly

US Bipolar Disorders Treatment Market By Healthcare Setting (USD Million, 2025-2035)

  • Outpatient
  • Inpatient
  • Residential Treatment Centers

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035